Skip to main content

Table 2 Age correlation with DAT activity, measured with FP-CIT SPECT and FE-PE2I PET

From: Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison

 

HC, n = 28

PS, n = 22

All

R

All

p

Female/male

R

All

R

All

p

Low DAT/normal DAT

R

Caudate

 FP-CIT, SUR

− 0.496

0.007

− 0.599*/− 0.360

− 0.354

0.107

− 0.565*/− 0.396

 FE-PE2I, BPND

− 0.577

0.001

− 0.803**/− 0.402

−0.569

0.006

− 0.679**/− 0.965**

 FE-PE2I, SUVR

− 0.502

0.007

− 0.796**/− 0.295

− 0.546

0.009

− 0.649**/− 0.970**

Putamen

 FP-CIT, SUR

− 0.400

0.035

− 0.543/− 0.161

− 0.207

0.355

− 0.612**/− 0.544

 FE-PE2I, BPND

− 0.540

0.003

− 0.697**/− 0.395

− 0.153

0.497

− 0.475 /− 0.564

 FE-PE2I, SUVR

− 0.430

0.022

− 0.556*/− 0.287

− 0.150

0.505

− 0.433 /− 0.698

Striatum

 FP-CIT, SUR

− 0.449

0.016

− 0.567*/− 0.280

− 0.267

0.230

− 0.602*/− 0.496

 FE-PE2I, BPND

− 0.588

0.001

− 0.780**/− 0.424

− 0.328

0.136

− 0.610**/− 0.832

 FE-PE2I, SUVR

− 0.480

0.010

− 0.675*/− 0.302

− 0.316

0.153

− 0.568*/− 0.916*

SN

 FE-PE2I, BPND

0.071

0.719

0.246 /− 0.117

− 0.175

0.436

− 0.333 /− 0.221

 FE-PE2I, SUVR

0.058

0.768

0.199/− 0.460

− 0.152

0.500

− 0.273 /− 0.139

  1. Correlations are calculated for mean DAT availability values in the respective compartments (averaged between the left and right hemispheres). Patients with low DAT n = 17, patients with normal DAT n = 5
  2. SUR specific uptake ratio, BPND binding potential relative to non-displaceable binding, SUVR specific uptake value ratio, SN substantia nigra, HC healthy controls, PS parkinsonian syndrome
  3. *Correlation is significant at the 0.05 level (two-tailed)
  4. **Correlation is significant at the 0.01 level (two-tailed)
  5. Correlation is not significant (two-tailed)